Rozanolixizumab Application Scope

Rozanolixizumab is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.

Rozanolixizumab Characteristics

Ingredients: Rozanolixizumab (a humanized IgG4 monoclonal antibody targeting the neonatal Fc receptor, FcRn)
Properties: A sterile, preservative-free, colorless to slightly yellowish solution for subcutaneous injection.
Packaging Specification: 280 mg/2 mL (140 mg/mL) in a single-dose glass vial; 1 vial per carton.
Storage: Store refrigerated (typically $2^{\circ} C$ to $8^{\circ} C$ ( $3 6^{\circ} F$ to $4 6^{\circ} F$ )). Do not freeze. Protect from light.
Expiry Date: Not available in general public information (consult product packaging/vial).
Executive Standard: Not available in general public information (consult prescribing information for specific standard).
Approval Number: To be provided according to local regulatory authority records.
Date of Revision: Not available in general public information (consult current prescribing information).
Manufacturer: UCB, Inc.

Guidelines for the Use of Rozanolixizumab

Dosage and Administration:
- Recommended Dose: Based on body weight, administered once weekly for 6 weeks: – Less than 50 kg: 420 mg SC infusion (3 mL) – 50 kg to less than 100 kg: 560 mg SC infusion (4 mL) – 100 kg and above: 840 mg SC infusion (6 mL)
- Administration: For subcutaneous infusion only, using an infusion pump. – Should be prepared and infused by a healthcare provider. – Infusion rate: up to 20 mL/hour. – Preferred sites: lower right or lower left part of the abdomen, below the belly button. Avoid areas that are tender, erythematous, or indurated.
- Missed Dose: Specific instructions for a missed dose should be provided by the healthcare provider. Consult the full prescribing information.
Adverse Reactions:
- Common Adverse Reactions:
  - Headache
  - Nausea
  - Diarrhea
  - Fever
  - Injection site reactions
- Serious Adverse Reactions:
  - Hypersensitivity or allergic reactions
  - Infections due to decreased IgG levels
Contraindications:
- Known hypersensitivity to rozanolixizumab or any component of the formulation
- Active or severe infections
Precautions:
- Infections: Delay in active infection; monitor for signs. Avoid live vaccines during treatment. Vaccinate per guidelines before new cycle.
- Aseptic meningitis: Monitor for symptoms (e.g., severe headache, neck stiffness); initiate diagnostic workup if suspected.
- Hypersensitivity: Monitor during/after infusion; discontinue if occurs.
- Pregnancy: May cause fetal harm based on animal data; use effective contraception. No data in lactation or pediatrics.

Rozanolixizumab Interactions

May reduce systemic exposure and effectiveness of medications binding to FcRn (e.g., immunoglobulins, Fc-containing monoclonal antibodies). Monitor closely; consider alternatives if long-term concomitant use is essential. No clinical drug interaction studies performed; not metabolized by CYP450 enzymes.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.